Disciplined Investors L.L.C. Acquires New Position in Johnson & Johnson (NYSE:JNJ)

Disciplined Investors L.L.C. acquired a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 1,922 shares of the company's stock, valued at approximately $278,000.

A number of other large investors have also recently made changes to their positions in JNJ. Principal Financial Group Inc. lifted its holdings in Johnson & Johnson by 10.5% during the 3rd quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company's stock worth $562,723,000 after buying an additional 329,473 shares during the last quarter. United Bank boosted its holdings in Johnson & Johnson by 5.6% in the third quarter. United Bank now owns 3,788 shares of the company's stock valued at $614,000 after purchasing an additional 202 shares in the last quarter. Resurgent Financial Advisors LLC increased its stake in Johnson & Johnson by 10.1% in the third quarter. Resurgent Financial Advisors LLC now owns 13,297 shares of the company's stock valued at $2,155,000 after purchasing an additional 1,217 shares during the last quarter. Royal London Asset Management Ltd. raised its holdings in Johnson & Johnson by 2.0% during the third quarter. Royal London Asset Management Ltd. now owns 1,626,795 shares of the company's stock worth $263,638,000 after purchasing an additional 31,334 shares in the last quarter. Finally, Quantinno Capital Management LP boosted its holdings in shares of Johnson & Johnson by 29.0% in the 3rd quarter. Quantinno Capital Management LP now owns 219,599 shares of the company's stock valued at $35,588,000 after buying an additional 49,307 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Insider Activity at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the company's stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of research reports. Argus raised shares of Johnson & Johnson to a "strong-buy" rating in a research report on Friday, January 24th. Wells Fargo & Company reduced their target price on Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a report on Thursday, January 23rd. Barclays lifted their price target on Johnson & Johnson from $159.00 to $166.00 and gave the stock an "equal weight" rating in a research report on Tuesday, January 28th. Royal Bank of Canada reissued an "outperform" rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday. Finally, Stifel Nicolaus cut their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating on the stock in a report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $171.33.

Johnson & Johnson Price Performance

Johnson & Johnson stock traded down $6.79 during midday trading on Friday, reaching $153.03. The company's stock had a trading volume of 16,594,687 shares, compared to its average volume of 7,800,054. The firm has a market capitalization of $368.77 billion, a PE ratio of 23.01, a P/E/G ratio of 2.56 and a beta of 0.49. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The stock's 50 day simple moving average is $159.75 and its 200 day simple moving average is $155.84. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter in the previous year, the firm earned $2.29 earnings per share. The firm's revenue was up 5.3% on a year-over-year basis. On average, equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.